吉貝爾(688566.SH):尼羣洛爾片在降低血壓的同時,又能降低心率
格隆匯7月28日丨有投資者向吉貝爾(688566.SH)提問:請問,貴公司的尼羣洛爾片的降壓特點有哪些?
吉貝爾回覆:公司尼羣洛爾片是國家首個複方抗高血壓一類新藥,用於治療輕中度原發性高血壓,更適用於輕中度高血壓合併心率快患者,是國內外首個鈣通道阻滯劑(CCB)+β受體阻滯劑(BB)組成的低劑量固定複方製劑,其創新性地運用了協同降壓機制,消減不良反應、提升療效,有效控制血壓,又能有效保護靶器官,擴大了適應範圍和人羣,減輕了藥物的副作用,提高了患者的依從性。尼羣洛爾片在降低血壓的同時,又能降低心率,針對高血壓合併心率快患者具有明顯的優勢,臨牀不可替代。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.